Cover Image
市場調查報告書

United Therapeutics Corporation:產品平台分析

United Therapeutics Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224585
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
United Therapeutics Corporation:產品平台分析 United Therapeutics Corporation - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 48 Pages
簡介

United Therapeutics Corporation是從事肺動脈高血壓等心血管疾病及感染疾病之治療藥的開發,商品化的生物科技企業。

本報告提供United Therapeutics Corporation的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

United Therapeutics Corporation的基本資料

United Therapeutics Corporation概要

  • 主要資訊
  • 企業資料

United Therapeutics Corporation:R&D概要

  • 主要的治療範圍

United Therapeutics Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

United Therapeutics Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

United Therapeutics Corporation:藥物簡介

  • dinutuximab
  • beraprost sodium LA
  • Placental Expanded
  • 心血管疾病的PLX細胞
  • esuberaprost sodium
  • Glycobiology Antiviral Agent
  • miglustat
  • treprostinil self injection
  • UV-4B

United Therapeutics Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

United Therapeutics Corporation:最近的開發平台趨勢

United Therapeutics Corporation:暫停中的計劃

United Therapeutics Corporation:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • 3F8-Mab
    • 8H9-MAb
    • UT-231B

United Therapeutics Corporation:企業發表

United Therapeutics Corporation:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07074CDB

Summary

Global Markets Direct's, 'United Therapeutics Corporation - Product Pipeline Review - 2015', provides an overview of the United Therapeutics Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of United Therapeutics Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of United Therapeutics Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of United Therapeutics Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the United Therapeutics Corporation's pipeline products

Reasons to buy

  • Evaluate United Therapeutics Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of United Therapeutics Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the United Therapeutics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of United Therapeutics Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of United Therapeutics Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of United Therapeutics Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • United Therapeutics Corporation Snapshot
    • United Therapeutics Corporation Overview
    • Key Information
    • Key Facts
  • United Therapeutics Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • United Therapeutics Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • United Therapeutics Corporation - Pipeline Products Glance
    • United Therapeutics Corporation - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • United Therapeutics Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • United Therapeutics Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • United Therapeutics Corporation - Drug Profiles
    • dinutuximab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • beraprost sodium SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX-PAD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UV-4B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • esuberaprost sodium ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Human Antibody Based Vaccines
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Insulin Producing Islet Cells
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • United Therapeutics Corporation - Pipeline Analysis
    • United Therapeutics Corporation - Pipeline Products by Target
    • United Therapeutics Corporation - Pipeline Products by Route of Administration
    • United Therapeutics Corporation - Pipeline Products by Molecule Type
    • United Therapeutics Corporation - Pipeline Products by Mechanism of Action
  • United Therapeutics Corporation - Recent Pipeline Updates
  • United Therapeutics Corporation - Dormant Projects
  • United Therapeutics Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • 8H-9
    • Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastom
      • UT-231B
  • United Therapeutics Corporation - Company Statement
  • United Therapeutics Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • United Therapeutics Corporation, Key Information
  • United Therapeutics Corporation, Key Facts
  • United Therapeutics Corporation - Pipeline by Indication, 2015
  • United Therapeutics Corporation - Pipeline by Stage of Development, 2015
  • United Therapeutics Corporation - Monotherapy Products in Pipeline, 2015
  • United Therapeutics Corporation - Partnered Products in Pipeline, 2015
  • United Therapeutics Corporation - Partnered Products/ Combination Treatment Modalities, 2015
  • United Therapeutics Corporation - Pre-Registration, 2015
  • United Therapeutics Corporation - Phase III, 2015
  • United Therapeutics Corporation - Phase I, 2015
  • United Therapeutics Corporation - Preclinical, 2015
  • United Therapeutics Corporation - Pipeline by Target, 2015
  • United Therapeutics Corporation - Pipeline by Route of Administration, 2015
  • United Therapeutics Corporation - Pipeline by Molecule Type, 2015
  • United Therapeutics Corporation - Pipeline Products by Mechanism of Action, 2015
  • United Therapeutics Corporation - Recent Pipeline Updates, 2015
  • United Therapeutics Corporation - Dormant Developmental Projects,2015
  • United Therapeutics Corporation - Discontinued Pipeline Products, 2015
  • United Therapeutics Corporation, Other Locations
  • United Therapeutics Corporation, Subsidiaries

List of Figures

  • United Therapeutics Corporation - Pipeline by Top 10 Indication, 2015
  • United Therapeutics Corporation - Pipeline by Stage of Development, 2015
  • United Therapeutics Corporation - Monotherapy Products in Pipeline, 2015
  • United Therapeutics Corporation - Partnered Products in Pipeline, 2015
  • United Therapeutics Corporation - Pipeline by Top 10 Target, 2015
  • United Therapeutics Corporation - Pipeline by Top 10 Route of Administration, 2015
  • United Therapeutics Corporation - Pipeline by Top 10 Molecule Type, 2015
  • United Therapeutics Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top